DSM Biologics and Argenes, Inc., headquartered in Tokyo, Japan, have signed a biopharmaceutical manufacturing agreement. Under the terms of the agreement, DSM will provide Argenes with full process development services, analytical development services and manufacturing batches for Argenes’ Anti-Fas IgM monoclonal antibody. The services will be provided out of DSM Biologics’ FDA-approved manufacturing facility in Groningen, The Netherlands. Argenes’ Anti-FAS IgM monoclonal antibody is being d...